Adjuvant therapy for patients with high-risk malignant melanoma

Seminars in Oncology

Volumn 29, Issue 4, 2002, Pages 389-399

  McClay, Edward F ^a,b,c  

^a San Diego Cancer Research Institute   (United States)

^b San Diego Melanoma Research Program   (United States)

^c Melanoma Research Center of San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CISPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEVAMISOLE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 2;

ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MELANOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION; VOMITING;

EID: 0036340606     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34118     Document Type: Article

References (58)

1. Interferon alfa-2a adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
2. High- and low-dose interferon alpha-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190
3. Model predicting survival in stage I melanoma based on tumor proression
4. Predicting outcome in patients with localized melanoma
5. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic
6. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
7. Multinstitutional melanoma lymphatic mapping experience: The prognostic valus of sentinel lymph node status in 612 stage I or II melanoma patients
8. Patterns of failure and survival in sentinel lymph node positive melanoma patients
9. Predicting the natural history of melanoma after tumor-negative sentinel lymph node dissection
10. Clinical significance of melanoma micrometastasis to sentinel lymph nodes and other high risk factors
11. Melanoma thickness and histology predict sentinel lymph nodes status
12. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma
13. Classification and staging
14. Initial assessment of positron emission tomography using 2-fluorine-18-fluro-2-deoxy-D-glucose in the imaging of malignant melanoma
15. Positron emission tomography in the detection and management of metastatic melanoma
16. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography; results of a prospective study of 100 patients
17. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
18. Prospective study fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy
19. Interferons in the treatment of human cancer
20. Interferons-clinical applications: Cutaneous melanoma
21. Results of adjuvant interferon study in WHO melanoma programme
22. Evaluation of efficacy of adjuvant rIFN-2A in melanoma patients with regional node metastases
23. Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomized study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma
24. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases form cutaneous melanoma: A randomised trial
25. High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of Intergroup trial E1694/S9512/C509801
26. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
27. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
28. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study
29. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma
30. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity
31. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
32. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma
33. An assesement of DTIC versus levamisole or placebo in the treatment of high risk stage I patients under surgical removal of a primary melanoma of the skin. A phase II adjuvant study (EORTC protocol 18761)
34. Improved survival in patients with poor-prognosis malignant melanoma treated wtih adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group
35. A randomized trial of levamisole versus placebe as adjuvant therapy in malignant melanoma
36. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma
37. Combination chemo/hormonal therapy in the treatment of malignant melanoma
38. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
39. Importance of tamoxifen to a combination chemotherapy regimen for melanoma
40. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma: A biologically important observation
41. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up
42. Effective chemotherapy for melanoma after treatment with interleukin-2
43. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: A University of South Florida and H. Lee Moffitt Melanoma Center study
44. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma
45. The chemohormonal therapy of metastatic melanoma: Possible benefit from tamoxifen
46. Aggressive chemotherapy for melanoma
47. Therapy for metastatic melanoma: Effective combination of dacarbazine, carmustine, cisplatin and tamoxifen
48. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma
49. Randomized phase II trial of BCDT (BCNU, cisplatin, dacarbazine and tamoxifen) with or without interferon alpha (IFN-alpha) and interleukin-2 (IL-2) in patients with metastatic melanoma
50. Phase III trial of melacine melanoma theracine versus combination chemotherapy in the treatment of stage IV melanoma
51. Phase II study of carmustine, dacarbazine, cisplatin and tamoxifen in advanced melanoma: A Southwest Oncology Group study
52. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastic melanoma
53. Modulation of cisplatin resistance in human malignant melanoma cells
54. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells
55. Tamoxifen delays the in vitro development of resistance to cisplatin in human malignancies
56. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies
57. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high-risk melanoma
58. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival